|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphomas (ALCLs) are CD30-positive T-cell non-Hodgkin lymphomas broadly segregated into ALK-positive and ALK-negative types.
|
30093402 |
2018 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Systemic anaplastic large cell lymphomas (ALCL) are a category of T-cell non-Hodgkin's lymphomas which can be divided into anaplastic lymphoma kinase (ALK) positive and ALK negative subgroups, based on ALK gene rearrangements.
|
29346274 |
2018 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These are a sub-type of non-Hodgkin's lymphomas that predominantly affect children and young adults and are characterized by the expression of the nucleophosmin (NPM)/ALK chimeric oncoprotein.
|
28771164 |
2017 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
A case of anaplastic lymphoma kinase-positive renal cell carcinoma coincident with Hodgkin lymphoma.
|
29024210 |
2017 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) is one of the most common T-cell non-Hodgkin lymphomas and has 2 main subtypes: an anaplastic lymphoma kinase (ALK)-positive subtype characterized by ALK gene rearrangements and an ALK-negative subtype that is poorly understood.
|
25390351 |
2015 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We compiled clinical and mutation data (EGFR, KRAS, and ALK) from the medical records of patients with LC and a remote history of HD.
|
25615851 |
2015 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hodgkin's lymphoma (HL) and ALK(+) anaplastic large-cell lymphoma (ALCL) have become highly curable due to the success of modern regimens of chemotherapy and radiotherapy.
|
24043362 |
2014 |
|
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic lymphoma kinase (ALK) was originally identified from a rare subtype of non-Hodgkin's lymphomas carrying t(2;5)(p23;q35) translocation, where ALK was constitutively activated as a result of a fusion with nucleophosmin (NPM).
|
22249260 |
2012 |
|
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
EML4-ALK transcripts were detected in 3/51 (5.9%) of reactive lymphoid tissues and 12/58 (20.7%) of lymphomas of different categories, including follicular lymphoma, diffuse large B-cell lymphoma and Hodgkin's disease.
|
19734424 |
2009 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
A subset of the proteins distinguished NPM/ALK-positive ALCLs from NPM/ALK-negative ALCLs and Hodgkin lymphoma.
|
19531656 |
2009 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
This study suggested that CD26 is selectively expressed on ALK-positive, but not on ALK-negative, ALCL and HL.
|
17071493 |
2006 |
|
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We studied 24 anaplastic large cell lymphomas (ALCL) classified by World Health Organization criteria [17 primary nodal/systemic (10 ALK+, 7 ALK-), seven primary cutaneous], and 17 additional non-Hodgkin's lymphomas [one ALK+ B-lineage lymphoma, 14 ALK- diffuse large B-cell lymphomas (seven anaplastic variants, five nonanaplastic, two secondary CD30+), two follicular lymphomas].
|
15475930 |
2005 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas.
|
16101126 |
2005 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that the CD30 promoter in tumor cells of both nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK)-positive and NPM-ALK-negative ALCL and HL is regulated by a constitutively active CD30-extracellular signal-regulated kinase (ERK) 1/2 mitogen-activated protein kinase (MAPK).
|
16140928 |
2005 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of anaplastic lymphoma kinase in non-Hodgkin's lymphomas and other malignant neoplasms. Biological, diagnostic, and clinical implications.
|
14569815 |
2002 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent immunohistologic studies, however, suggest that ALCLs Hodgkin-like represent either cases of tumor cell-rich classic Hodgkin disease or (less commonly) ALK(+) ALCL or ALK(-) ALCL.(Blood.2000;96:3681-3695)
|
11090048 |
2000 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our group recently demonstrated NPM/ALK fusion cDNAs by single-cell RT-PCR in < 3% of CD30+ tumour cells in 2/9 cases of HD.
|
9886332 |
1998 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aggregate results of these studies indicate that the t(2;5) translocation or other somatic mutations resulting in inappropriate expression of ALK are involved rarely if at all in the pathogenesis of Hodgkin's disease, but may be present in about 10% of cases of lymphomatoid papulosis and 20% of cases of CD30+ primary cutaneous large cell lymphoma.
|
9638979 |
1998 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
NPM-ALK is rarely, if ever, detected in Hodgkin's disease or secondary ALCL.
|
9684923 |
1998 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data indicate that NPM/ALK fusion transcripts do not play an early role in the pathogenesis of HD.
|
9209648 |
1997 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
All other cases comprising T or null ALCL (17 cases), B ALCL (8 cases), Hodgkin's disease (HD) (15 cases), HD-like ALCL (23 cases), and lymphomatoid papulosis (9 cases), were negative for ALK expression.
|
9250148 |
1997 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overall, 6 (3 T and 3 null) of 49 ALCL and 3 (2 nodular sclerosis and 1 mixed cellularity) of 72 HD showed the presence of NPM-ALK transcripts by RT-PCR.
|
8562933 |
1996 |
|
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecular analysis of the NPM-ALK rearrangement in Hodgkin's disease.
|
8683377 |
1996 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease.
|
8781433 |
1996 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, NPM/ALK transcripts were not detected in any of the 34 cases of HD or in the 19 cases of T-NHL.
|
7662979 |
1995 |